Latest Insider Transactions at Century Therapeutics, Inc. (IPSC)
This section provides a real-time view of insider transactions for Century Therapeutics, Inc. (IPSC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Century Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Century Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,033
-0.76%
|
$1,033
$1.23 P/Share
|
|
Nov 04
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
283
-0.09%
|
$283
$1.23 P/Share
|
|
Nov 01
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
16,611
-4.97%
|
$16,611
$1.26 P/Share
|
|
Oct 14
2024
|
Morgan Conn Chief Finanical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,148
+50.0%
|
-
|
|
Oct 01
2024
|
Chad Cowan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,376
+26.08%
|
-
|
|
Sep 12
2024
|
Daphne Quimi Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$5,000
$1.53 P/Share
|
|
Aug 05
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
289
-0.09%
|
$289
$1.83 P/Share
|
|
Aug 05
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,073
-0.78%
|
$1,073
$1.83 P/Share
|
|
Jul 26
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
586
-0.21%
|
$1,172
$2.5 P/Share
|
|
Jul 24
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
1,600
-0.58%
|
$3,200
$2.52 P/Share
|
|
Jul 23
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
200
-0.07%
|
$400
$2.5 P/Share
|
|
Jun 20
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.77%
|
$10,000
$2.84 P/Share
|
|
Jun 07
2024
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
17,007
+4.84%
|
-
|
|
Jun 05
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.74%
|
$15,000
$3.0 P/Share
|
|
May 20
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.71%
|
$15,000
$3.0 P/Share
|
|
May 06
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.68%
|
$15,000
$3.12 P/Share
|
|
May 03
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
913
-0.66%
|
$2,739
$3.11 P/Share
|
|
May 03
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
257
-0.08%
|
$771
$3.11 P/Share
|
|
Apr 22
2024
|
Gregory Russotti Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.65%
|
$15,000
$3.1 P/Share
|
|
Mar 07
2024
|
Brent Pfeiffenberger President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
17,425
+1.17%
|
-
|
|
Mar 07
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+14.8%
|
-
|
|
Mar 07
2024
|
Gregory Russotti Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+7.35%
|
-
|
|
Mar 07
2024
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+4.22%
|
-
|
|
Mar 07
2024
|
Hyam Levitsky President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+50.0%
|
-
|
|
Mar 07
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
22,831
-16.67%
|
$114,155
$5.14 P/Share
|
|
Mar 07
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,831
+14.29%
|
$22,831
$1.03 P/Share
|
|
Mar 06
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
30,684
-21.19%
|
$122,736
$4.96 P/Share
|
|
Mar 06
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,684
+17.48%
|
$30,684
$1.03 P/Share
|
|
Feb 16
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
485
-0.42%
|
$1,940
$4.86 P/Share
|
|
Feb 16
2024
|
Adrienne Farid Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+0.42%
|
$485
$1.03 P/Share
|
|
Feb 06
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
1,784
-1.54%
|
$7,136
$4.49 P/Share
|
|
Feb 06
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
557
-0.18%
|
$2,228
$4.49 P/Share
|
|
Feb 05
2024
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
2,035
-1.73%
|
$6,105
$3.84 P/Share
|
|
Feb 05
2024
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
643
-0.21%
|
$1,929
$3.84 P/Share
|
|
Dec 04
2023
|
Brent Pfeiffenberger President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,453,279
+33.07%
|
-
|
|
Nov 01
2023
|
Douglas Carr SVP Finance & Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
16,611
-5.17%
|
$16,611
$1.49 P/Share
|
|
Nov 01
2023
|
Michael Craig Diem Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,763
-7.57%
|
$20,763
$1.49 P/Share
|
|
May 15
2023
|
Michael Craig Diem Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
151,058
+35.51%
|
-
|
|
May 15
2023
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
120,846
+27.33%
|
-
|
|
Apr 03
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,452
+2.82%
|
$7,452
$1.03 P/Share
|
|
Mar 23
2023
|
Luis Borges Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,597
-5.89%
|
$46,791
$3.55 P/Share
|
|
Mar 23
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220,930
+45.5%
|
$220,930
$1.03 P/Share
|
|
Mar 22
2023
|
Luis Borges Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
65,698
-60.03%
|
$197,094
$3.72 P/Share
|
|
Mar 22
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
65,698
+37.51%
|
$65,698
$1.03 P/Share
|
|
Mar 21
2023
|
Luis Borges Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
63,616
-59.25%
|
$190,848
$3.77 P/Share
|
|
Mar 21
2023
|
Luis Borges Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,616
+37.21%
|
$63,616
$1.03 P/Share
|
|
Feb 02
2023
|
Adrienne Farid Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+17.09%
|
-
|
|
Feb 02
2023
|
Luis Borges Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+41.67%
|
-
|
|
Feb 02
2023
|
Douglas Carr SVP Finance & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+3.67%
|
-
|
|
Feb 02
2023
|
Michael Craig Diem Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+16.41%
|
-
|